- Home
- RGNX
RGNX
REGENXBIO Inc.
as 11-21-2024 4:00pm EST
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | ROCKVILLE |
| Market Cap: | 459.1M | IPO Year: | 2015 |
| Target Price: | $36.36 | AVG Volume (30 days): | 886.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.54 - $28.80 | Next Earning Date: | 11-06-2024 |
| Revenue: | $84,327,000 | Revenue Growth: | -15.14% |
| Revenue Growth (this year): | 7.91% | Revenue Growth (next year): | 214.75% |
Stock Insider Trading Activity of REGENXBIO Inc. (RGNX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| KARABELAS ARGERIS N | RGNX | Director | Oct 1 '24 | Sell | $10.11 | 10,000 | $101,052.00 | 11,286 | |
| KARABELAS ARGERIS N | RGNX | Director | Sep 3 '24 | Sell | $11.92 | 10,000 | $115,588.00 | 11,286 |
Latest REGENXBIO Inc. News
RGNX Breaking Stock News: Dive into RGNX Ticker-Specific Updates for Smart Investing
Pharmaceutical Technology
2 days ago
Regenxbio eyes 2026 filing for Duchenne muscular dystrophy gene therapy
MT Newswires
3 days ago
Update: Regenxbio Shares Rise After Positive Phase I/II Data on RGX-202 Gene Therapy for Duchenne Muscular Dystrophy
MT Newswires
3 days ago
Sector Update: Health Care Stocks Mixed Premarket Monday
MT Newswires
3 days ago
Regenxbio Reports Positive Phase I/II Data on RGX-202 Gene Therapy for Duchenne Muscular Dystrophy - Shares Up Pre-Bell
PR Newswire
3 days ago
REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA
BioPharma Dive
4 days ago
FDA endorses speedy approval path for Regenxbio Duchenne gene therapy
PR Newswire
7 days ago
REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202
Argus Research
9 days ago
RGNX: Raising target price to $11.00
Compare RGNX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RGNX REGENXBIO Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.